NasdaqGM:NTLABiotechs
A Look At Intellia Therapeutics (NTLA) Valuation After Safety Concerns And HAE Market Uncertainty
Recent commentary on Intellia Therapeutics (NTLA) is focused on safety concerns and regulatory pauses in its transthyretin amyloidosis program, as well as questions about commercial potential for its hereditary angioedema therapy.
See our latest analysis for Intellia Therapeutics.
Intellia's recent safety headlines come on top of sharp price swings. The company recorded a 1 day share price return of negative 7.99% following a 30 day share price return of 52.55%. Its 1 year total shareholder...